medigraphic.com

2021, Number 1

<< Back Next >>

Enf Infec Microbiol 2021; 41 (1)

Evaluation with the Likert scale taste acceptance, of three commercial brands of sulfametoxazol/ trimetroprim in liquid form

Reyes HMU, Lira RC, Echeverría MC, Reyes HKL, Hernández MR, Hernández LI, López CG, Quero HA, Reyes GU

Language: Spanish
References: 27
Page: 17-21
PDF size: 251.15 Kb.


ABSTRACT

Introduction. Sulfamethoxazole with trimethoprim (s/t) has different indications in acute and chronic bacterial infections in children. Flavor of this drug is definitive for its acceptance, and for exact dose compliance and therefore the success of the treatment.
Objective. To know the acceptance of three different brands of s/t in its liquid presentation, in a group of university students.
Population and method. Observational, prospective, comparative and blinded study. Taste and acceptance of s/t of three commercial brands in suspension were evaluated (bactrim, ectaprim and bactropim). Forty five students were included, they were in fasting conditions and their clinical history did not show allergy data to the drugs used or an acid-peptic and liver diseases history. Likert scale was used for acceptance evaluation, granting a preference score on 1-5 scale. Between every evaluation, mouthwash with water was performed. Written consent was requested from all participants.
Results. A total of 45 students participated. The average acceptance score was higher for the drug ectaprim (4.08), followed by bactrim (3.69) and bactroprim (2.20). In the ANOVA test at least one group showed a statistically significant difference. In the analysis by subsets, the taste of the drug bactroprim was statistically less accepted than the other drugs (p ‹0.001). Although the taste acceptance score was higher for ectaprim, there was no statistical difference with the acceptance of the drug bactrim (p = 0.165). No variable (age, weight, body mass index) showed a correlation with giving a higher or lower score to each drug.
Discussion. Ectaprim’s trademark had the best acceptance in 79.44%, followed by bactrim in 66.67%. The one with the worst acceptance in 60% was bactropim. These results must be considered for the prescription of those with the best acceptance due to their best taste in their liquid presentation.


REFERENCES

  1. Cazorla, S.M. y Rodríguez, D.D., “Grado de adherencia terapéutica a los fármacos del metabolismo óseo-mineral: ¿toman nuestros pacientes la medicación prescrita?”, Enf Nefrol, 2013, 16 (1): 41-47.

  2. Belloso, H.W., “Historia de los antibioticos”, Rev Hosp Ital B Aires, 2029, 29 (2): 48-111.

  3. Arias, P.J., “Comparación entre ciprofloxacina y antibióticos de otros grupos farmacológicos para el tratamiento de infecciones del tracto urinario”, Universidad de Costa Rica, revista electrónica, 2017; 32.

  4. Espín, I.M., Aguilera, A.D., García, P.A. y Baquero, A.F., “Neumonía adquirida en la comunidad resistente a meticilina Staphylococcus aureus en lactantes”, Enf Infec y Microb Clín, 2019, 37 (8): 551-552.

  5. Byron, M.D., Hooper, C.D. y Mitty, J., “Trimethoprimsulfamethoxazole: an overview Up Todate 2020, 1 (09). Disponible en: https://www.uptodate.com/contents/ trimethoprim-sulfamethoxazole-an-overview.

  6. Comité de Medicamentos de la Asociación Española de Pediatría, Pediamécum, 2015. Disponible en: https:// www.aeped.es/comite-medicamentos/pediamecum/ trimetoprim. Consultado el 17/11/2019.

  7. Williams, G. y Craig, J.C., “Long-term antibiotics for preventing recurrent urinary tract infection in children”, Cochrane Database of Systematic Reviews, 2019, 4: CD001534. doi: 10.1002/14651858.CD001534.pub4.

  8. Onakpoya, I.J., Hayward, G. y Heneghan, C.J., “Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under”, Cochrane Database of Systematic Reviews, 2015, 9, Art. No.: CD011530. doi: 10.1002/14651858.CD011530.pub2.

  9. National Institute of Diabetes and Digestive and Kidney Diseases, “Sulfamethoxazole-trimethoprim”, 2017. Disponible en: https://www.ncbi.nlm.nih.gov/books/ NBK547937.

  10. Ramírez, R.O., “Obstáculos para la elaboración de escalas tipo Likert: una reflexión personal”, Medicina Familiar, 2007, 9 (2): 75-84.

  11. Lerdal, A.A., Kottorp, C., Gay, B.E. Aouizerat, C.J., Portillo, K.A. y Lee, A. “7-item version of the fatigue severity scale has better psychometric properties among hivinfected adults: an application of a Rasch model”, Qual Life Res, 2011, 20: 1447-1465.

  12. Duarte, R.E., Velasco, B.E., Sánchez, S.J. y Reyes, L.L., “Validación psicométrica de la escala de gravedad de fatiga en médicos residentes”, Educ Med, 2019, 20 (1): 28-36. Disponible en: https://www.who.int/features/ factfiles/obesity/facts/es/.

  13. Delwiche, J.F., “The impact of perceptual interactions on perceived flavor”, Food Qual Pref, 2004, 15: 137-146.

  14. Forestall, C.A. y Mennella, J.A., “The ontogeny of taste perception and preference throughout childhood”, en Doty, R.L. (ed.), Handbook of olfaction and gustation, 3ª ed., Nueva York, John Wiley and Sons, 2015, pp. 795-830.

  15. Beauchamp, G.K. y Mennella, J.A., “Early flavor learning and its impact on later feeding behavior”, J Pediatr Gastr Nutr, 2009, 48: s25-s30.

  16. García, J.E., “Incumplimiento como causa de problema relacionado con medicamentos en el seguimiento farmacéutico”, tesis doctoral, Granada, 2013.

  17. “Adherencia terapéutica con carbonato de lantano”, Sociedad Española de Nefrología, 2013, 4 (2): 1-54.

  18. Tentori, F., Blayney, M.J., Albert, J.M., Gillespie, B.W., Kerr, P.G., Bommer, J. et al., “Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and pth: the Dialysis Outcomes and Practice Patterns Study (dopps)”, Am J Kidney Dis, 2008, 52 (3): 519-530.

  19. Villegas, R.X., Ruíz, E.H. y Bárcenas, P.E., “Tecnologías de enmascaramiento del sabor amargo de los alimentos” Temas Selectos de Ingeniería de Alimentos, 2010, 4 (1): 27-33.

  20. Schiffman, S.S., “Influence of medications on taste and smell”, World J Otorhinolaryngol Head Neck Surg, 2018, 4 (1): 84-91.

  21. Wang, T., Glendinning, J., Grushka, M. et al., “Drug-induced taste disorders in clinical practice and preclinical safety evaluation”, Toxicol Sci, 2017, 156 (2): 315-324.

  22. Doty, R.L., Shah, M. y Bromley, S.M., “Drug-induced taste disorders”, Drug Saf, 2008, 31 (3): 199-215.

  23. Reyes, H.K., Reyes, G.U., Reyes, H.H., Guerrero, B.M., Gutiérrez, P.D., Santos, S.N. et al., “Evaluación de la aceptación de azálidos y macrólidos en presentación reconstituida y en presentación líquida”, Enf Infec Microb, 2019, 39 (2): 56-59.

  24. Chávez, B.S. y Stull, T.L., “Antibacterial agents in pediatrics”, Infect Dis Clin Nort Am, 2009, 23: 865-888.

  25. Gutiérrez, O.B., Saltigeral, S.P., Reyes, B.M., Granja, B.V. y Alcalá, P.M., “Comparación del olor, cuerpo, sabor y sensación posterior a la ingesta que producen cinco ampicilinas y dos trimetropin sulfametoxazol en presentación líquida con sabor distinto”, Rev Mex Puer Ped, 2002, 10 (55): 7-24.

  26. Lowry, J.A., Jones, B.L., Sandritter, T.L. y Kearns, G.L., “Principles of drug therapy”, en Kliegman, R.M., Stanton, B.F., St. Geme, J.W. y Schor, N.F. (eds.), Nelson Textbook of Pediatrics, 20ª ed., Filadelfia, Elsevier, 2016, cap. 60.

  27. Ryu, G.S. y Lee, Y.J., “Analysis of liquid medication dose errors made by patients and caregivers using alternative measuring devices”, J Manag Care Pharm, 2012, 18 (6): 439-445. pmid: 22839684, www.ncbi.nlm.nih.gov/ pubmed/22839684.




2020     |     www.medigraphic.com